Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLCJoao V. Alessi, Mark M. Awad, Grace M. Hambelton et al.|Journal of Thoracic Oncology|2023Cited by 91
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D’Alessio, David J. Pinato, Bernardo Stefanini et al.|The Lancet Oncology|2024Cited by 64
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Fable Zustovich, Giuseppe Cabibbo et al.|Journal of Hepatology|2023Cited by 62
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Johann von Felden, Giuseppe Cabibbo et al.|Hepatology|2024Cited by 52
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in ItalyValentina Burgio, Andrea Casadei‐Gardini, Massimo Iavarone et al.|Cancer Management and Research|2021Cited by 38